Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs Standard Therapy in CFRD
NCT00222521Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Apr 2003
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin glargine in cystic fibrosis-related diabetes (CFRD) (2 arms), sponsored by University of Minnesota. Primary endpoint: Hemoglobin A1c. Started Apr 2003; status: completed.
02
Drugs
insulin glargine
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT00222521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00222521.